The success of anti-epidermal growth factor receptor (anti-EGFR) therapy for patients of the Kras non-mutation group of colorectal cancer has raised the expectation that other malignancies, such as Kras non-mutation group of ovarian MC can also be treated with comparable success rates. This evidence concerns the gene KRAS and colorectal cancer.